Patents by Inventor Angélique Patiny-Adam

Angélique Patiny-Adam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS
    Publication number: 20240279237
    Abstract: The invention relates to novel compounds having the general formula Ic wherein R1, R2, R3, R8, R9, RX, A1, A2, W and n are as described herein, composition including the compounds and methods of using the compounds.
    Type: Application
    Filed: April 17, 2024
    Publication date: August 22, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lewis Scott AITKEN, Lea Aurelie BOUCHE, Wolfgang GUBA, Georg JAESCHKE, Heather Jennifer JOHNSTON, Stefanie Katharina MESCH, Angélique PATINY-ADAM, Christian SCHNIDER, Jonathan Martin SHANNON, Sandra STEINER, Andreas TOSSTORFF
  • NOVEL COMPOUNDS
    Publication number: 20240132471
    Abstract: The invention relates to novel compounds having the general formula Ib wherein R1, R2, R1, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 30, 2023
    Publication date: April 25, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lea Aurelie BOUCHE, Wolfgang GUBA, Georg JAESCHKE, Stefanie Katharina MESCH, Angélique PATINY-ADAM, Christian SCHNIDER, Sandra STEINER, Andreas Michael TOSSTORFF
  • Isoxazolyl ether derivatives as GABA?5 PAM
    Patent number: 11840528
    Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: December 12, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
  • NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20230142171
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: October 4, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Roland HUMM, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT, Christian SCHNIDER
  • NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA 1 PAM
    Publication number: 20230136326
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: September 28, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andreas KOBLET, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT
  • NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM
    Publication number: 20210094945
    Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
  • Substituted pyrazino[2,2-a]isoquinoline derivatives
    Patent number: 10316036
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: June 11, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES
    Publication number: 20180037582
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 8, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • Substituted pyrazino[2,2-a]isoquinoline derivatives
    Patent number: 9828374
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: November 28, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES
    Publication number: 20170145010
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R2and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Application
    Filed: February 8, 2017
    Publication date: May 25, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
    Patent number: 8487102
    Abstract: The present invention relates to a compound of formula I wherein R1, R2, R3, Ar, and n are as defined herein or to a pharmaceutically active acid addition salt. Compounds of formula I show a high affinity simultaneously to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor antagonists), useful in the treatment of schizophrenia.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: July 16, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Philippe Jablonski, Matthias Nettekoven, Angelique Patiny-Adam, Hasane Ratni, Heinz Stadler
  • Pyrrolidines as NK3 receptor antagonists
    Patent number: 8394834
    Abstract: The present invention relates to a compounds of formula I wherein R1, R2, Ar1, Ar2, R?, R?, m, n, and o are defined in the specification or to a pharmaceutically active salt, racemic mixture, enantiomer, optical isomer or to tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: March 12, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Philippe Jablonski, Henner Knust, Matthias Nettekoven, Angelique Patiny-Adam, Hasane Ratni, Claus Riemer
  • Pyrrolidine derivatives as NK-3 receptor antagonists
    Patent number: 8293770
    Abstract: The present invention relates to a compound of formula I wherein Ar1, Ar2, R1, R2, R3, n, o, and p are as described herein or to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 23, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Philippe Jablonski, Henner Knust, Matthias Nettekoven, Angelique Patiny-Adam, Hasane Ratni, Claus Riemer
  • PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS
    Publication number: 20110257402
    Abstract: The present invention relates to a compound of formula I wherein R1, R2, R3, Ar, and n are as defined herein or to a pharmaceutically active acid addition salt. Compounds of formula I show a high affinity simultaneously to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor antagonists), useful in the treatment of schizophrenia.
    Type: Application
    Filed: April 11, 2011
    Publication date: October 20, 2011
    Inventors: Philippe Jablonski, Matthias Nettekoven, Angëlique Patiny-Adam, Hasane Ratni, Heinz Stadler
  • PYRROLIDINES AS NK3 RECEPTOR ANTAGONISTS
    Publication number: 20110053948
    Abstract: The present invention relates to a compounds of formula I wherein R1, R2, Ar1, Ar2, R?, R?, m, n, and o are defined in the specification or to a pharmaceutically active salt, racemic mixture, enantiomer, optical isomer or to tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
    Type: Application
    Filed: August 16, 2010
    Publication date: March 3, 2011
    Inventors: Philippe Jablonski, Henner Knust, Matthias Nettekoven, Angélique Patiny-Adam, Hasane Ratni, Claus Riemer
  • PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS
    Publication number: 20100168088
    Abstract: The present invention relates to a compound of formula I wherein Ar1, Ar2, R1, R2, R3, n, o, and p are as described herein or to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
    Type: Application
    Filed: October 2, 2009
    Publication date: July 1, 2010
    Inventors: Caterina Bissantz, Philippe Jablonski, Henner Knust, Matthias Nettekoven, Angélique Patiny-Adam, Hasane Ratni, Claus Riemer